Johnson & Johnson said Thursday the average price paid for its medicines in the U.S. fell by 4.6% last year due to the company’s discounts, and the company’s pharmaceuticals chief expects the pricing pressures on drugmakers will continue this year. J&J, one of the biggest sellers of prescription drugs in the U.S., said it raised the list prices for its medicines by an average 8.1%, but they wound up as a whole costing far less because the manufacturer handed out $15 billion in discounts and rebates.

Source: Wall Street Journal March 08, 2018 23:24 UTC